Visiongain Publishes Mycoplasma Testing Market Report 2020-2030

24 July 2020
Pharma

Visiongain has launched a new report Mycoplasma Testing Market Report 2020-2030: Forecasts by Products (Instruments, Kits & Reagents (PCR Assays, Nucleic Acid Detection Kits, Stains, Elimination Kits, Standards & Controls, and Others) and Services), by Technique (PCR, ELISA, Direct Assays, Indirect Assays, DNA Staining, Microbial Culture Techniques, and Enzymatic Methods), by Application (Cell Line Testing, Virus Testing, End-of Production Cell Testing, and Others), by End-user (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, Cell Banks, and Others) and by Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). Including Forecasts by Major Developed Countries and Developing Countries, Plus Profiles of Leading Companies in the Market.

Mycoplasmas are the smallest self-replicating organisms which has minimal genome that cannot perform metabolic functions such as production of a cell wall, or synthesis of nucleotides or amino acids. Therefore, they exist strictly as parasites, using diverse organisms as hosts, including humans, animals, insects and plants. Mycoplasma is responsible for causing respiratory tract infection. Mycoplasma can be tested using polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), enzymatic reaction, or DNA staining. Mycoplasma testing is extensively carried out in pharmaceutical manufacturing industries at several phases of product development to examine its contamination in raw materials and final drug products. It is also performed to identify the presence of Mycoplasma in cell banks and biotechnology laboratories, if not, it can further spoil the cell culture-based research work.

Due to less number of culture methods, researchers are highly focused and involved in the identification and development of more rapid and accurate mycoplasma tests in recent years. The prime advantage of such rapid tests is the high sensitivity, capability of identifying a wide range of mycoplasma species, and cycle time reduction, which further reduces the production time. These rapid methods would also expedite the decision making to minimize the spread of contamination. Leading examples of alternative method for culture-based testing are Nucleic Acid-based Technology (NAT) and Polymerase Chain Reaction (PCR) based service that helps detect contaminants in mycoplasma cell cultures driving the market growth.

The pharmaceutical and biotechnology market across several geographies is growing at a significant rate. According to the International Trade Administration, the global pharmaceuticals market is projected to grow to $1.3 trillion by 2020. As stated by the India Brand Equity Foundation (IBEF), the Indian pharmaceuticals market is expected to reach $55 billion by 2020. Strong growth in the pharmaceutical and biopharmaceutical industries is anticipated to drive the mycoplasma testing market.

The Visiongain report analyst commented “that the pharmaceutical and biotechnology companies are the leading end users where mycoplasma testing is carried out in the research and production of all biopharmaceutical products. Growth in the pharmaceutical and biotechnology sector across the globe serves as a direct driver for supplementary markets such as mycoplasma testing.”

However, for optimal efficacy, mycoplasma testing needs to be conducted by skilled professionals and also needs a certain level of expertise in handling the instruments used in mycoplasma testing. Consequently, the dearth of a sufficiently skilled workforce poses a key challenge to the growth of the mycoplasma testing market.

The report covers a detailed competitive outlook that includes market share and company profiles of key players operating in the global market. Key players profiled in the report include Bionique Testing Laboratories, Inc., Lonza Group Ltd., Merck KGaA; PromoCell GmbH, ATCC (American Type Culture Collection), Biological Industries Israel Beit Haemek Ltd., Charles River Laboratories International, Inc., Thermo Fisher Scientific, and InvivoGen.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031

Due to increases in the therapies in progress, the dosages provided, & the patient populations targeted, viral vector production capacity has become increasingly reduced in recent years. The condition is aggravated by COVID-19.

03 December 2020

Read

Visiongain Publishes Drugs of Abuse Testing Market Report 2021-2031

Drugs Abuse has risen very significantly in few last year as compared to previous once and expected to continuously rise over the forecast period. The increase in the drugs abuse creates a huge demand for the drugs of abuse testing products.

03 December 2020

Read

Visiongain Publishes Controlled Substance Market Report 2021-2031

Continuous increasing prevalence of chronic pain is increasing demand for controlled substance as treatment for Chronic pain. Due to which increasing prevalence of chronic pain around the world is working as a driver for the controlled substance market.

03 December 2020

Read

Visiongain Publishes Companion Animal Diagnostics Market Report 2021-2031

All regions are facing rapid growth in the companion animal population. Companion animal are at high risk of developing various diseases for which companion animal require timely diagnosis for the identification, detection and treatment for life causing diseases.

03 December 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever